| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
189,490,000 |
| Market
Cap: |
1.17(B) |
| Last
Volume: |
2,941,111 |
Avg
Vol: |
4,440,946 |
| 52
Week Range: |
$4.13 - $7.98 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : 16.9 |
| Insider 6 Months : 16.9 |
| Insider 3/6 Months : 32.4 |
|
| Guru Rank Number : 455 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BioCryst Pharmaceuticals is a commercial-stage biotechnology company that discovers oral, small-molecule medicines. Co. focuses on oral treatments for rare diseases. Co.'s drug/drug candidates include: ORLADEYO™ (berotralstat), an oral serine protease inhibitor targeting kallikrein that is being developed for the prevention of Hereditary Angioedema attacks; BCX9930, an oral factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors for the treatment of fibrodysplasia ossificans progressive; and RAPIVAB® (peramivir injection), an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
183,601 |
183,601 |
183,601 |
183,601 |
| Total Buy Value |
$1,048,338 |
$1,048,338 |
$1,048,338 |
$1,048,338 |
| Total People Bought |
10 |
10 |
10 |
10 |
| Total Buy Transactions |
10 |
10 |
10 |
10 |
| Total Shares Sold |
0 |
0 |
0 |
495,199 |
| Total Sell Value |
$0 |
$0 |
$0 |
$5,999,241 |
| Total People Sold |
0 |
0 |
0 |
9 |
| Total Sell Transactions |
0 |
0 |
0 |
14 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Staab Thomas R Ii |
Senior Vice President and CFO |
• • – |
2018-01-20 |
4 |
D |
$5.59 |
$22,243 |
D/D |
(3,979) |
137,383 |
|
- |
|
| Stonehouse Jon P |
President & CEO |
• • – |
2018-01-20 |
4 |
D |
$5.59 |
$53,575 |
D/D |
(9,584) |
638,367 |
|
- |
|
| Barnes Alane P |
VP, General Counsel & Corp Sec |
• • – |
2018-01-20 |
4 |
D |
$5.59 |
$10,962 |
D/D |
(1,961) |
77,129 |
|
- |
|
| Sheridan William P |
Senior VP - CMO |
• • – |
2018-01-20 |
4 |
D |
$5.59 |
$25,871 |
D/D |
(4,628) |
18,058 |
|
- |
|
| Staab Thomas R Ii |
Senior Vice President and CFO |
• • – |
2018-01-01 |
4 |
D |
$4.91 |
$4,183 |
D/D |
(852) |
141,362 |
|
- |
|
| Babu Yarlagadda S |
Senior VP - Drug Discovery |
• • – |
2018-01-01 |
4 |
D |
$4.91 |
$4,115 |
D/D |
(838) |
103,868 |
|
- |
|
| Barnes Alane P |
VP, General Counsel & Corp Sec |
• • – |
2018-01-01 |
4 |
D |
$4.91 |
$2,254 |
D/D |
(459) |
79,090 |
|
- |
|
| Stonehouse Jon P |
President & CEO |
• • – |
2018-01-01 |
4 |
D |
$4.91 |
$13,336 |
D/D |
(2,716) |
647,951 |
|
- |
|
| Sheridan William P |
Senior VP - CMO |
• • – |
2018-01-01 |
4 |
D |
$4.91 |
$5,740 |
D/D |
(1,169) |
22,686 |
|
- |
|
| Hutson Nancy J |
Director |
• • – |
2017-12-01 |
4 |
A |
$5.08 |
$9,997 |
D/D |
1,968 |
36,135 |
|
- |
|
| Ingram Robert Alexander |
Director |
• • – |
2017-12-01 |
4 |
A |
$5.08 |
$18,745 |
D/D |
3,690 |
15,130 |
|
- |
|
| Sheridan William P |
Senior VP - CMO |
• • – |
2017-11-13 |
4 |
AS |
$4.72 |
$303,543 |
D/D |
(64,310) |
23,855 |
|
- |
|
| Cohen Fred E |
Director |
• • – |
2017-09-18 |
4 |
S |
$5.42 |
$294,035 |
D/D |
(54,250) |
119,410 |
|
- |
|
| Cohen Fred E |
Director |
• • – |
2017-09-18 |
4 |
OE |
$4.27 |
$231,648 |
D/D |
54,250 |
173,660 |
|
- |
|
| Ingram Robert Alexander |
Director |
• • – |
2017-09-01 |
4 |
A |
$5.10 |
$18,748 |
D/D |
3,676 |
11,440 |
|
- |
|
| Hutson Nancy J |
Director |
• • – |
2017-09-01 |
4 |
A |
$5.10 |
$9,996 |
D/D |
1,960 |
34,167 |
|
- |
|
| Cohen Fred E |
Director |
• • – |
2017-06-01 |
4 |
A |
$5.15 |
$9,996 |
D/D |
1,941 |
119,410 |
|
- |
|
| Hutson Nancy J |
Director |
• • – |
2017-06-01 |
4 |
A |
$5.15 |
$9,996 |
D/D |
1,941 |
32,207 |
|
- |
|
| Ingram Robert Alexander |
Director |
• • – |
2017-06-01 |
4 |
A |
$5.15 |
$9,996 |
D/D |
1,941 |
7,764 |
|
- |
|
| Staab Thomas R Ii |
Senior Vice President and CFO |
• • – |
2017-05-22 |
4 |
D |
$5.24 |
$36,659 |
D/D |
(6,996) |
142,214 |
|
- |
|
| Staab Thomas R Ii |
Senior Vice President and CFO |
• • – |
2017-05-22 |
4 |
OE |
$4.73 |
$36,658 |
D/D |
7,750 |
149,210 |
|
- |
|
| Staab Thomas R Ii |
Senior Vice President and CFO |
• • – |
2017-03-20 |
4 |
AS |
$9.20 |
$29,900 |
D/D |
(3,250) |
141,460 |
|
- |
|
| Staab Thomas R Ii |
Senior Vice President and CFO |
• • – |
2017-03-20 |
4 |
OE |
$3.78 |
$12,285 |
D/D |
3,250 |
144,710 |
|
- |
|
| Staab Thomas R Ii |
Senior Vice President and CFO |
• • – |
2017-03-16 |
4 |
D |
$8.80 |
$108,310 |
D/D |
(12,308) |
141,460 |
|
- |
|
| Staab Thomas R Ii |
Senior Vice President and CFO |
• • – |
2017-03-16 |
4 |
OE |
$1.42 |
$108,300 |
D/D |
36,455 |
153,768 |
|
- |
|
753 Records found
|
|
Page 14 of 31 |
|
|
0.06 (0.96%) 
